Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 May;96(2):297–302. doi: 10.1111/j.1365-2249.1994.tb06557.x

Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies.

G G Oliveira 1, P R Hutchings 1, I M Roitt 1, P M Lydyard 1
PMCID: PMC1534883  PMID: 8187337

Abstract

NZB mice spontaneously develop haemolytic anaemia as the result of production of erythrocyte autoantibodies. The mechanisms leading to breakdown in tolerance to erythrocyte autoantigens are unknown. Antibodies to CD4 have been successfully used to treat several murine models of autoimmune disease. In this study we injected NZB mice with non-depleting CD4 antibodies and were able to prevent and abrogate erythrocyte autoantibody production in young (Coombs' negative) and old (Coombs' positive) mice, respectively. Our data indicate the dependency of autoantibody production on CD4+ T cells. However, withdrawal of anti-CD4 antibodies resulted in the appearance of erythrocyte autoantibodies, showing that under these conditions we were unable to re-establish tolerance to autoantigens on erythrocytes using anti-CD4 treatment.

Full text

PDF
297

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman N. E., Watling D. L., McDevitt H. O. Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med. 1983 Oct 1;158(4):1350–1355. doi: 10.1084/jem.158.4.1350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ando D. G., Sercarz E. E., Hahn B. H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol. 1987 May 15;138(10):3185–3190. [PubMed] [Google Scholar]
  3. Barker R. N., de Sá Oliveira G. G., Elson C. J., Lydyard P. M. Pathogenic autoantibodies in the NZB mouse are specific for erythrocyte band 3 protein. Eur J Immunol. 1993 Jul;23(7):1723–1726. doi: 10.1002/eji.1830230750. [DOI] [PubMed] [Google Scholar]
  4. Barthold D. R., Kysela S., Steinberg A. D. Decline in suppressor T cell function with age in female NZB mice. J Immunol. 1974 Jan;112(1):9–16. [PubMed] [Google Scholar]
  5. Benjamin R. J., Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature. 1986 Apr 3;320(6061):449–451. doi: 10.1038/320449a0. [DOI] [PubMed] [Google Scholar]
  6. Berzofsky J. A., Richman L. K. Genetic control of the immune response to myoglobins. IV. Inhibition of determinant-specific Ir gene-controlled antigen presentation and induction of suppression by pretreatment of presenting cells with anti-Ia antibodies. J Immunol. 1981 May;126(5):1898–1904. [PubMed] [Google Scholar]
  7. Cantor H., McVay-Boudreau L., Hugenberger J., Naidorf K., Shen F. W., Gershon R. K. Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: absence in NZB mice. J Exp Med. 1978 Apr 1;147(4):1116–1125. doi: 10.1084/jem.147.4.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cooke A., Hutchings P. R., Playfair J. H. Suppressor T cells in experimental autoimmune haemolytic anaemia. Nature. 1978 May 11;273(5658):154–155. doi: 10.1038/273154a0. [DOI] [PubMed] [Google Scholar]
  9. DeHeer D. H., Edgington T. S. Evidence for a B lymphocyte defect underlying the anti-X anti-erythrocyte autoantibody response of NZB mice. J Immunol. 1977 May;118(5):1858–1863. [PubMed] [Google Scholar]
  10. Goldberg D., Morel P., Chatenoud L., Boitard C., Menkes C. J., Bertoye P. H., Revillard J. P., Bach J. F. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun. 1991 Aug;4(4):617–630. doi: 10.1016/0896-8411(91)90181-b. [DOI] [PubMed] [Google Scholar]
  11. Gutstein N. L., Seaman W. E., Scott J. H., Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15;137(4):1127–1132. [PubMed] [Google Scholar]
  12. HELYER B. J., HOWIE J. B. Spontaneous auto-immune disease in NZB/BL mice. Br J Haematol. 1963 Apr;9:119–131. doi: 10.1111/j.1365-2141.1963.tb05450.x. [DOI] [PubMed] [Google Scholar]
  13. HOLMES M. C., GORIE J., BURNET F. M. Transmission by splenic cells of an autoimmune disease occurring spontaneously in mice. Lancet. 1961 Sep 16;2(7203):638–639. doi: 10.1016/s0140-6736(61)90313-0. [DOI] [PubMed] [Google Scholar]
  14. Hafler D. A., Ritz J., Schlossman S. F., Weiner H. L. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 1;141(1):131–138. [PubMed] [Google Scholar]
  15. Hayakawa K., Hardy R. R., Honda M., Herzenberg L. A., Steinberg A. D., Herzenberg L. A. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2494–2498. doi: 10.1073/pnas.81.8.2494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Herzog C., Walker C., Pichler W., Aeschlimann A., Wassmer P., Stockinger H., Knapp W., Rieber P., Müller W. Monoclonal anti-CD4 in arthritis. Lancet. 1987 Dec 19;2(8573):1461–1462. doi: 10.1016/s0140-6736(87)91158-5. [DOI] [PubMed] [Google Scholar]
  17. Horneff G., Burmester G. R., Emmrich F., Kalden J. R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 1991 Feb;34(2):129–140. doi: 10.1002/art.1780340202. [DOI] [PubMed] [Google Scholar]
  18. Hutchings P. R., Cooke A., Dawe K., Waldmann H., Roitt I. M. Active suppression induced by anti-CD4. Eur J Immunol. 1993 Apr;23(4):965–968. doi: 10.1002/eji.1830230431. [DOI] [PubMed] [Google Scholar]
  19. Hutchings P., O'Reilly L., Parish N. M., Waldmann H., Cooke A. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur J Immunol. 1992 Jul;22(7):1913–1918. doi: 10.1002/eji.1830220735. [DOI] [PubMed] [Google Scholar]
  20. Koike T., Itoh Y., Ishii T., Ito I., Takabayashi K., Maruyama N., Tomioka H., Yoshida S. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes. 1987 Apr;36(4):539–541. doi: 10.2337/diab.36.4.539. [DOI] [PubMed] [Google Scholar]
  21. Miller R. D., Calkins C. E. Active role of T cells in promoting an in vitro autoantibody response to self erythrocytes in NZB mice. Immunology. 1988 Apr;63(4):625–630. [PMC free article] [PubMed] [Google Scholar]
  22. Moore J. S., Calkins C. E. In vitro regulation of the pathogenic autoantibody response of New Zealand black mice. I. Loss with age of suppressive activity in T cell populations. J Immunol. 1985 Jun;134(6):3838–3844. [PubMed] [Google Scholar]
  23. Murakami M., Tsubata T., Okamoto M., Shimizu A., Kumagai S., Imura H., Honjo T. Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature. 1992 May 7;357(6373):77–80. doi: 10.1038/357077a0. [DOI] [PubMed] [Google Scholar]
  24. Perry L. L., Greene M. I. Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. J Exp Med. 1982 Aug 1;156(2):480–491. doi: 10.1084/jem.156.2.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Qin S. X., Cobbold S., Benjamin R., Waldmann H. Induction of classical transplantation tolerance in the adult. J Exp Med. 1989 Mar 1;169(3):779–794. doi: 10.1084/jem.169.3.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Qin S. X., Wise M., Cobbold S. P., Leong L., Kong Y. C., Parnes J. R., Waldmann H. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol. 1990 Dec;20(12):2737–2745. doi: 10.1002/eji.1830201231. [DOI] [PubMed] [Google Scholar]
  27. Qin S., Cobbold S. P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. "Infectious" transplantation tolerance. Science. 1993 Feb 12;259(5097):974–977. doi: 10.1126/science.8094901. [DOI] [PubMed] [Google Scholar]
  28. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Scott B. B., Sadigh S., Stow M., Mageed R. A., Andrew E. M., Maini R. N. Anti-mouse red blood cell monoclonal antibodies use functionally rearranged genes from the VH J558 family and are derived from the CD5- B-lymphocyte subpopulation. Immunology. 1993 Aug;79(4):568–573. [PMC free article] [PubMed] [Google Scholar]
  30. Shibata T., Berney T., Reininger L., Chicheportiche Y., Ozaki S., Shirai T., Izui S. Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms. Int Immunol. 1990;2(12):1133–1141. doi: 10.1093/intimm/2.12.1133. [DOI] [PubMed] [Google Scholar]
  31. Shizuru J. A., Taylor-Edwards C., Banks B. A., Gregory A. K., Fathman C. G. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988 Apr 29;240(4852):659–662. doi: 10.1126/science.2966437. [DOI] [PubMed] [Google Scholar]
  32. Sriram S., Roberts C. A. Treatment of established chronic relapsing experimental allergic encephalomyelitis with anti-L3T4 antibodies. J Immunol. 1986 Jun 15;136(12):4464–4469. [PubMed] [Google Scholar]
  33. Sriram S., Steinman L. Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J Exp Med. 1983 Oct 1;158(4):1362–1367. doi: 10.1084/jem.158.4.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Staples P. J., Talal N. Relative inability to induce tolerance in adult NZB and NZB-NZW F1 mice. J Exp Med. 1969 Jan 1;129(1):123–139. doi: 10.1084/jem.129.1.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Steinman L., Rosenbaum J. T., Sriram S., McDevitt H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111–7114. doi: 10.1073/pnas.78.11.7111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Waldor M. K., Sriram S., McDevitt H. O., Steinman L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci U S A. 1983 May;80(9):2713–2717. doi: 10.1073/pnas.80.9.2713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Warner N. L., Wistar R., Jr Immunoglobulins in NZB-BL mice. I. Serum immunoglobulin levels and immunoglobulin class of erythrocyte autoantibody. J Exp Med. 1968 Jan 1;127(1):169–183. doi: 10.1084/jem.127.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wassmer P., Chan C., Lögdberg L., Shevach E. M. Role of the L3T4-antigen in T cell activation. II. Inhibition of T cell activation by monoclonal anti-L3T4 antibodies in the absence of accessory cells. J Immunol. 1985 Oct;135(4):2237–2242. [PubMed] [Google Scholar]
  39. Wofsy D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol. 1986 Jun 15;136(12):4554–4560. [PubMed] [Google Scholar]
  40. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES